Nita Shah, MD
Nephrology · West Orange, NJNPI 1538139399
Payments from drug & device makers
Across 20 payments — averaging $98.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Takeda Pharmaceuticals U.S.A., Inc.$250
- AstraZeneca$116
- Travere Therapeutics, Inc.$101
- Vifor Pharma, Inc.$96
- Otsuka America Pharmaceutical, Inc.$61
- plus $59 from 3 others
What the payments were for
- Speaking & faculty fees$1,35669%
- Food & beverage$37819%
- Education$24512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 8 | $1,296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $250 |
| AstraZeneca | 2 | $116 |
| Travere Therapeutics, Inc. | 3 | $101 |
| Vifor Pharma, Inc. | 1 | $96 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Baxter Healthcare | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,979 in reported general payments places this provider in the 60th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 33 | $90,975 |
| Sevelamer Carbonate | 31 | $3,089 |
| Calcium Acetate | 15 | $2,939 |
| Tacrolimus | 12 | $2,916 |
| Clonidine | 13 | $2,116 |
| Mycophenolate Mofetil | 17 | $1,831 |
| Midodrine Hcl | 22 | $1,115 |
| Hydralazine Hcl | 33 | $620 |
| Amlodipine Besylate | 55 | $608 |
| Metoprolol Succinate | 22 | $412 |
| Prednisone | 45 | $395 |
| Torsemide | 16 | $381 |
| Pantoprazole Sodium | 39 | $262 |
| Losartan Potassium | 23 | $229 |
| Gabapentin | 16 | $225 |
Paid to pharmacies, not to this prescriber.
Other nephrology in West Orange
- Anup PatelWest Orange$1M
- Danny HaddadJersey City$1.7M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.